Kidney Cancer

The liquid biopsy test was also approved as a companion diagnostic test to uncover EGFR mutations in patients with NSCLC who could benefit from treatment with Tagrisso.
 

Dr. Toni K. Choueiri discusses what therapies are currently available for patients with metastatic renal cell carcinoma, as well as what new treatments could be on the horizon.
 

The FDA based its decision on data from a phase 2 trial which showed that MK-6482 induced clinical responses among patients with von Hippel-Lindau disease-associated kidney cancer.
 

While the combination of Opdivo and Yervoy is one of several treatment options for patients with metastatic renal cell carcinoma, many patients will likely progress after initial treatment. However, new research shows that when used after immune checkpoint inhibition, the combination shows promise.
 

Data from a phase 2 study presented during the 2020 ASCO Virtual Scientific Program demonstrated that Avastin (bevacizumab) in combination with Tarceva (erlotinib) was well tolerated and produced encouraging clinical outcomes in patients with advanced hereditary leiomyomatosis and renal cell carcinoma or sporadic papillary renal cell carcinoma.
 

Data from a phase 3 study presented at the 2020 ASCO Virtual Scientific Program showed that treatment with savolitinib demonstrated encouraging efficacy and an improved safety over standard-of-care Sutent (sunitinib) in patients with MET-driven papillary renal cell carcinoma.
 

A roundup of the latest news and updates for patients with Renal Cell Carcinoma from CURE®.
 

A variety of novel treatments, including immunotherapies, extend life for patients with advanced kidney cancer.

Getting kidney cancer treatment during the COVID-19 pandemic.

Kidney cancer positives that might come from this pandemic.